Lets add in some clindamycin

Clindamycin seems to be being used more frequently (just an anecdotal observation). The Archivist has always held clindamycin in reserve for careful use as an adjuvant to using β-lactam antibiotics for the more severe group A β-haemolytic streptococcal invasive infections (iGAS) such as necrotising fasciitis. Is there good evidence of a benefit in the use of clindamycin in treating patients with invasive non-group A/B β-haemolytic streptococcal (iNABS) infections? Babiker A et al. [Lancet Infectious Dis 2021 https://ift.tt/2x0kxcY S1473-3099(20)30523-5] have published the findings of a retrospective multicentre cohort study, using a dataset from adult patients in an electronic health-based from 233 hospitals based in the United States of America. The authors have examined the database for inpatients admitted to hospital in 2000–15, with any clinical cultures positive for β-haemolytic streptococcal bacterium, and who had received β-lactam antibiotics within 3 days either side of culture sampling. This group of...

from Archives of Disease in Childhood current issue https://ift.tt/3szAzrL